Pharming Group NV (PHAR) Social Stream
PHARMING GROUP NV (PHAR) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering PHAR.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
Over the past 21 months, PHAR's average price target has gone down $4.5.
PHAR reports an average of 254.42% for its upside potential over the past 44 weeks.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
PHAR Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
PHAR's average broker recommendation rating improved by 0 over the prior 39 weeks.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In the context of all US stocks, PHARMING GROUP NV's number of analysts covering the stock is greater than 26.51% of them.
- PHARMING GROUP NV's variance in analysts' estimates is lower than 72.82% of all US stocks.
- PHAR has a greater average analyst price target than 503.15% of stocks in the small market cap category.
- In the context of stocks in the small market cap category, PHARMING GROUP NV's upside potential (average analyst target price relative to current price) is higher than 403.2% of them.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to PHARMING GROUP NV are GRCL, EFTR, and ANGN.
View All Top Stocks by Price Target
Is PHAR a Buy, Hold or Sell? See the POWR Ratings now!